182 related articles for article (PubMed ID: 20053325)
1. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study.
Searles G; Bissonnette R; Landells I; Shear NH; Papp K; Lui H
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S131-8. PubMed ID: 20053325
[TBL] [Abstract][Full Text] [Related]
2. Efficacy outcomes in patients using alefacept in the AWARE study.
Landells I; Searles G; Bissonnette R; Shear NH; Vender R; Lui H
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S122-30. PubMed ID: 20053324
[TBL] [Abstract][Full Text] [Related]
3. The AWARE study: methodology and baseline characteristics.
Bissonnette R; Searles G; Landells I; Shear NH; Papp K; Lui H; Gulliver WP; Lynde C
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S113-21. PubMed ID: 20053323
[TBL] [Abstract][Full Text] [Related]
4. Update on alefacept safety.
Wexler D; Searles G; Landells I; Shear NH; Bissonnette R; Papp K; Poulin Y; Langley R; Gulliver WP
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S139-47. PubMed ID: 20053326
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
6. The next phase of real-world clinical experience with alefacept: the AWARE-2 registry.
Searles G; Bissonnette R; Landells I; Shear NH
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S148-52. PubMed ID: 20053327
[No Abstract] [Full Text] [Related]
7. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
8. Preface: real-world clinical experience with alefacept-the Amevive Wisdom Acquired from Real-World Evidence (AWARE) study.
Searles G; Bissonnette R; Landells I; Shear NH
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S107-12. PubMed ID: 20053322
[No Abstract] [Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
[TBL] [Abstract][Full Text] [Related]
10. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
11. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.
Legat FJ; Hofer A; Wackernagel A; Salmhofer W; Quehenberger F; Kerl H; Wolf P
Arch Dermatol; 2007 Aug; 143(8):1016-22. PubMed ID: 17709660
[TBL] [Abstract][Full Text] [Related]
12. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.
Krueger GG
J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():17-24. PubMed ID: 12795771
[TBL] [Abstract][Full Text] [Related]
13. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC
J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311
[TBL] [Abstract][Full Text] [Related]
14. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
[TBL] [Abstract][Full Text] [Related]
15. Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
[TBL] [Abstract][Full Text] [Related]
16. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
[TBL] [Abstract][Full Text] [Related]
17. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
[TBL] [Abstract][Full Text] [Related]
18. Alefacept treatment for chronic plaque psoriasis.
Dunn LK; Feldman SR
Skin Therapy Lett; 2010 Apr; 15(4):1-3. PubMed ID: 20361167
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
20. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
